Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Trial shows promise for facial tumour cure
Lead author Dr Cesar Tovar said the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.
Immunotherapy shrank tumours in Tasmanian devils

Scientists say they have had a ‘eureka’ moment in using immunotherapy to cure Tasmanian devils of the deadly devil facial tumour disease (DFTD).

Led by the University of Tasmania, an international research team used immunotherapy on devils with golf-ball-sized tumours and observed the tumours shrinking and disappearing over a period of three months.

“This is almost a eureka moment for us because it’s the first time we can say for sure that it was the immunotherapy that was making the tumour shrink,” said Professor Greg Woods, who led the team at the university’s Menzies Institute for Medical Research.

Lead author Dr Cesar Tovar added that the findings confirm it is possible to trigger the devil’s immune system to recognise and destroy DFTD tumours.

“Our research shows that a DFTD vaccine is feasible. We are focusing our efforts on developing strategies to improve the devils’ response to immunisation.”

The breakthrough is the next step on from research published in 2015, which revealed the devil’s immune system was capable of mounting an immune response to DFTD.

“This is an important step along the way to developing a vaccine to protect against DFTD and potentially to cure devils of established DFTD,” Prof Woods added.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.